AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks
This article was originally published in The Pink Sheet Daily
Executive Summary
Olaparib and TC-5214 development setbacks at AstraZeneca lead to $380 million charge in the fourth quarter, with core EPS likely at the bottom of the expected range.